Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 8/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9910109 | 0.82 | MET (0.61) | METUSP30 | |
| SCHEMBL18231499 | 0.78 | MET (0.59) | MET | |
| SCHEMBL2697256 | 0.74 | MET (0.71) | MET | |
| SCHEMBL14311546 | 0.74 | MET (0.57) | MET | |
| SCHEMBL28834146 | 0.73 | DYRK1A (0.55) | METUSP30KDRPIK3CD | |
| SCHEMBL28834148 | 0.73 | DYRK1A (0.55) | METUSP30KDRPIK3CD | |
| SCHEMBL2698016 | 0.72 | MET (0.68) | MET | |
| SCHEMBL28834299 | 0.70 | ALDH1A1 (0.54) | USP30PIK3CD | |
| SCHEMBL28834297 | 0.70 | ALDH1A1 (0.54) | USP30PIK3CD | |
| SCHEMBL24010678 | 0.70 | MET (0.54) | METPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | MET 3/4885USP30 3750/4885AURKA 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.